Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma, including the first relapse setting. In the MajesTEC-9 trial, ...
1. Selected dates can't be greater than March 2026. 2. From date can't be greater than To date. 1. Selected dates can't be greater than March 2026. 2. From date can't be greater than To date. 1. From ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results